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Introduction
Neutrophils are first responders to invading pathogens, with either their absence or dysfunction resulting in an 
immunocompromised state (1). In viral infections, neutrophils are quickly recruited, ameliorate local tissue 
Neutrophils provide a critical line of defense in immune responses to various pathogens, 
inflicting self-damage upon transition to a hyperactivated, procoagulant state. Recent work 
has highlighted proinflammatory neutrophil phenotypes contributing to lung injury and acute 
respiratory distress syndrome (ARDS) in patients with coronavirus disease 2019 (COVID-19). Here, 
we use state-of-the art mass spectrometry–based proteomics and transcriptomic and correlative 
analyses as well as functional in vitro and in vivo studies to dissect how neutrophils contribute 
to the progression to severe COVID-19. We identify a reinforcing loop of both systemic and 
neutrophil intrinsic IL-8 (CXCL8/IL-8) dysregulation, which initiates and perpetuates neutrophil-
driven immunopathology. This positive feedback loop of systemic and neutrophil autocrine 
IL-8 production leads to an activated, prothrombotic neutrophil phenotype characterized 
by degranulation and neutrophil extracellular trap (NET) formation. In severe COVID-19, 
neutrophils directly initiate the coagulation and complement cascade, highlighting a link to the 
immunothrombotic state observed in these patients. Targeting the IL-8–CXCR-1/-2 axis interferes 
with this vicious cycle and attenuates neutrophil activation, degranulation, NETosis, and IL-8 
release. Finally, we show that blocking IL-8–like signaling reduces severe acute respiratory 
distress syndrome of coronavirus 2 (SARS-CoV-2) spike protein–induced, human ACE2–
dependent pulmonary microthrombosis in mice. In summary, our data provide comprehensive 
insights into the activation mechanisms of neutrophils in COVID-19 and uncover a self-sustaining 
neutrophil–IL-8 axis as a promising therapeutic target in severe SARS-CoV-2 infection.
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damage, and limit systemic viral spread by contributing to both clearance of  infected tissue and production of  
antiviral cytokines (2, 3). However, their antimicrobial activity also causes harm. In particular, the excessive 
release of  neutrophil extracellular traps (NETs) and cytotoxic granule contents contributes to self-inflicted 
damage to both local and remote organs (4–6). This process of  immunopathology is a hallmark of  severe 
coronavirus disease 2019 (COVID-19) and contributes to respiratory failure, progressive immune dysregula-
tion and — ultimately — death (7–10). Therefore, limiting immunopathology might be a promising therapeu-
tic strategy to improve outcomes in COVID-19. This is supported by the efficacy of  corticosteroid treatment 
in pneumonic COVID-19 (11). Consequently, it is crucial to increase our understanding of  immune dysregu-
lation in critical cases of  severe acute respiratory distress syndrome of  coronavirus 2 (SARS-CoV-2) infection.
We and others have shown that neutrophil hyperactivation and NET formation contribute to the occurrence 
of immunothrombosis in COVID-19 and correlate with disease severity (12–15). Transcriptomics have revealed 
striking changes in the neutrophil compartment, including mobilization of bone marrow–derived immature 
neutrophils with a unique proinflammatory signature (9, 16). Nevertheless, neutrophil protein composition and 
content, granule release, and recruitment mechanism data across COVID-19 disease states are scarce.
Here, we use state-of-the-art mass spectrometry–based proteomics, transcriptomic, and correlative 
analyses of  clinical data combined with functional in vitro and in vivo studies to characterize neutrophils 
in COVID-19. In severe disease, we demonstrate a degranulated, prothrombotic neutrophil phenotype in 
peripheral blood characterized by upregulation of  pathways associated with the response to and production 
of  IL-8. Neutrophils recruited to the lung express IL-8, which in turn activates and enhances IL-8 release 
of  peripheral neutrophils. In line with this finding, we identify increased plasma IL-8 levels in a cohort of  
patients with COVID-19 with severe disease but no increase in patients with mild-to-moderate disease. Block-
ing this pathway attenuates NET formation, degranulation, and neutrophil activation. Finally, targeting the 
IL-8 receptors CXCR-1/-2 in a murine model of  SARS-CoV-2 spike protein–induced lung injury ameliorates 
neutrophil-driven pulmonary microthrombosis. In summary, our data suggest a systemic and autocrine IL-8–
CXCR-1/-2 axis at the center of  neutrophil-driven immunopathology in severe COVID-19.
Results
Neutrophil proteomics reveal strong IFN responses and enhanced IL-8 signaling in COVID-19. Because neutrophils 
are a main cellular factor contributing to disease progression in COVID-19, we set out to investigate their 
functional status at the protein level in patient samples. To this end, we recruited patients with COVID-19 
with intermediate or severe disease and compared them with patients hospitalized for non–COVID-19 viral 
pneumonias (Pneu) and with healthy controls (Ctrl). Patients with COVID-19 requiring normal ward inpa-
tient hospital care were grouped into the intermediate cohort (Int), patients requiring additional invasive 
ventilation or intensive care treatment were included in the severe cohort (Sev). We profiled the proteome 
of  peripheral blood neutrophils using tandem mass tag mass spectrometry (Supplemental Figure 1, A and 
B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.150862DS1). 
A total of  5087 neutrophil proteins were identified. Our comprehensive neutrophil protein atlas is available 
online at https://neuprocov.mdc-berlin.de and includes a graphical interface to interrogate neutrophil pro-
tein dynamics in response to SARS-CoV-2 and other viral pneumonias compared with healthy controls.
3D principal component analysis (PCA) of  all proteins and differentially regulated proteins sepa-
rated neutrophils of  patients with COVID-19 from both healthy control patients and patients with non–
COVID-19 pneumonia (Figure 1A and Supplemental Figure 1D). In addition, we observed a trend toward 
differential clustering according to disease severity in COVID-19 (Figure 1, A and B, and Supplemental 
Figure 1, C–E). Sorted cells also included immature neutrophils characterized by low expression of  mem-
brane metalloendopeptidase (MME)/CD10, a neutrophil subset that has been described to be especially 
prominent in COVID-19 (Figure 1C) (17).
Recently, several landmark studies have revealed the role of  IFN-induced transcriptional changes in gene 
expression and the immune response to SARS-CoV-2 infection (18–21). We confirmed this finding at the 
protein level: Neutrophils from patients with COVID-19 were enriched for IFN stimulated gene (ISG) prod-
ucts, with both intermediate and severe cases, compared with control patients without COVID-19, exhibiting 
elevated levels of  canonical ISG products, such as IFN-induced protein with tetratricopeptide repeats 1 
(IFIT1), IFN-induced GTP-binding protein MX1 and IFN-induced transmembrane protein 3 (IFITM3, Fig-
ure 1D) (22), and, consequently, a marked increase in computed ISG scores (Figure 1E). We and others have 
hypothesized that an early and strong upregulation of  ISGs is a hallmark of  protective immune response to 
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SARS-CoV-2, thereby preventing systemic inflammatory spillover associated with severe COVID-19 cases 
(16, 23). In line with this concept, neutrophils from mild-to-moderate cases exhibited stronger IFN responses 
compared with neutrophils from patients requiring intensive care treatment (Figure 1E).
Clinical and experimental data point toward a critical contribution of  neutrophils to disease progres-
sion (8). To better understand how these antivirally tuned neutrophils might mediate the transition from 
COVID-19 pneumonia to respiratory failure we compared intermediate and severe cohorts. Biological net-
work analyses using ClueGO yielded increased detection of  proteins associated with a response to IL-8 
in severe COVID-19 and a molecular skewing toward IL-8 production as the most dominant pathways in 
neutrophils (Figure 2A and Supplemental Figure 1F). In detail, transmembrane receptor CD74 and TLR-4, 
-5, and -8, which were shown to be upregulated in response to neutrophil stimulation and to trigger neu-
trophil IL-8 production (24), were increased in patients with severe COVID-19 (Figure 2B). We comput-
ed a global IL-8 score defined by enrichment of  IL-8–associated and –induced proteins, which revealed a 
significant enrichment of  these proteins exclusively in patients with severe COVID-19 pneumonia (Figure 
2C). High IL-8 scores correlated with pulmonary disease severity of  COVID-19, assessed by the Horowitz 
index (paO2/FiO2) (Figure 2D). In addition, we found a positive correlation between increased IL-8 scores 
and elevated D-dimer plasma levels, pointing toward an association of  IL-8 with coagulation dysregulation 
(Figure 2E) (12). Hence, the neutrophil proteome signature discriminates between mild and severe courses 
of  COVID-19. Consistent with previous reports on elevated systemic IL-8 levels, we found increased plasma 
IL-8 levels in patients with severe COVID-19 compared with control patients without COVID-19, in an 
independent cohort (n = 133, Figure 2F). In summary, increased ISG protein detection in neutrophils char-
acterizes mild-to-moderate disease, whereas severe COVID-19 is associated with elevation of  IL-8–induced 
protein pathways, corresponding with systemic increases in plasma IL-8.
IL-8 production loops sustained by pulmonary and peripheral blood neutrophils characterize severe COVID-19. 
We next hypothesized that IL-8 might be a central player involved in pulmonary recruitment of  neutro-
phils and disease progression of  COVID-19. Therefore, we analyzed publicly available scRNA-Seq data of  
bronchoalveolar lavage fluid from healthy controls in comparison to mild-to-moderate and patients with 
Figure 1. Neutrophil proteomics reveal imma-
ture neutrophils with a strong IFN response 
in COVID-19. (A) Principal component analysis 
of neutrophils of patients, by group. Proteins 
with adjusted P value of less than 0.1 were 
included for this PCA. (B) Positions of patient 
neutrophil samples on principal component 
axis 1 (PC 1). One-way ANOVA. (C) Box plot of 
CD10 abundance (log-scaled median-MAD nor-
malized abundance) of neutrophils by group. 
Abundance is normalized with median-MAD 
method. Significance is adjusted P values. 
(D) Heat map of mean IFN-stimulated genes 
(ISG) protein abundance on neutrophils by 
group. (E) Box plot of ISG score calculated from 
log-scaled abundance values (see methods) on 
neutrophils by group. One-way ANOVA with 
post hoc Holm-Sidak’s multiple comparisons 
test to control. (A–E), n = 9 healthy control, n 
= 5 pneumonic control, n = 5 severe COVID-19 
and n = 9 intermediate patients with COVID-19. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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severe COVID-19 (25) and specifically focused on chemokine transcription in different pulmonary cell 
populations. Our analysis revealed the presence of  IL-8 mRNA specifically in severe COVID-19 (Supple-
mental Figure 2, A and B), with neutrophil-like cells recruited to the alveolar space showing the strongest 
pulmonary IL-8 expression, followed by epithelial cells, monocytes and monocytic macrophages (Supple-
mental Figure 2C). Among relevant chemokines, IL-8 mRNA showed the strongest increase in neutrophils, 
with no elevated levels of  IL-6 and IL-1alpha, and an increase in IL-1β mRNA that did not reach the same 
extent as IL-8 mRNA in neutrophils (Supplemental Figure 2D).
To compare COVID-19 to non–COVID-19 pneumonic patients rather than healthy controls, we addition-
ally made use of  a recently published scRNA-Seq data set by Wauters and colleagues (26), which included 
a high count of  captured neutrophils in the dataset (Figure 3, A and B). This analysis confirmed that neu-
trophilic IL-8 mRNA transcription in patients with severe COVID-19 significantly surpassed expression of  
IL-8–encoding transcripts in both mild-to-moderate COVID-19 as well as non–COVID-19 mild pneumonia 
(Figure 3C). In line with our previous finding, gene expression analysis across all other detected immune and 
nonimmune cell types confirmed neutrophils as a main source of  pulmonary IL-8 (Figure 3D).
Severe COVID-19 has been linked to cytokine shock syndromes (27–29). Recent studies revealed syn-
ergistic and self-sustaining cytokine loops as a central element of  cytokine shock pathophysiology (30). 
Considering both our proteomic and transcriptomic analyses pointing toward IL-8 production/release by 
Figure 2. Severe COVID-19 neutrophils upregulate proteins implicated in IL-8 signaling. (A) ClueGo upregulated neutrophil proteome pathway grouping of 
severe COVID-19 compared with intermediate COVID-19. (B) Heatmap of mean IL-8 pathway protein abundance on neutrophils by group. (C) Box plot of IL-8 
score calculated from log-scaled abundance values (see methods) by group. One-way ANOVA with post hoc Tukey’s multiple comparisons test between all 
groups. (A–C) n = 9 healthy control, n = 5 pneumonic control, n = 5 severe COVID-19 and n = 9 intermediate patients with COVID-19. (D and E) Linear regres-
sion of Horowitz index (PaO2/FiO2) or clinically measured D-dimer (μg/mL) and IL-8 score of patients with COVID-19. P value signifies slope significantly 
non-zero. 95% confidence interval shown in gray. n = 5 severe and 9 intermediate patients with COVID-19. (F) Box plot of normalized serum IL-8 plasma 
levels of COVID-19 and control patients. n = 26 control patients without COVID-19, n = 78 patients with mild-moderate COVID-19 (WHO Grade 1–4), n = 29 
severe COVID-19 (WHO Grade 5–8) patients. One-way ANOVA with post hoc Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001.
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peripheral and pulmonary neutrophils, respectively, we hypothesized that a loop of  neutrophil intrinsic 
IL-8 production with both systemic and autocrine features may drive neutrophil activation and recruit-
ment. Therefore, we stimulated healthy neutrophils with recombinant IL-8 in vitro to mimic the systemic 
effects of  IL-8 (Figure 3E). Interestingly, stimulation with either IL-8 or the neutrophil activating agent 
PMA induced IL-8 release within two hours of  exposure (Figure 3F). Elevated levels of  other proinflam-
matory cytokines like IL-1β and IL-6 in both infected lungs and plasma have been linked to COVID-19 
severity (25, 31–34). However, unlike IL-8, IL-1β, and IL-6 did not lead to pronounced IL-8 release by 
neutrophils within the observed time frame (Figure 3F). Carryover of  recombinant IL-8 was excluded in 
our setup using PFA-fixated neutrophils (Supplemental Figure 2E).
These data indicate a harmful cycle of  neutrophil-derived pulmonary and systemic IL-8, which in turn 
might sustain both auto- and paracrine as well as systemic activation loops, aggravating pulmonary neutro-
phil influx, and local hyperstimulation.
COVID-19 neutrophils are characterized by IL-8–induced degranulation and drive a systemic prothrombotic pheno-
type. Next, we sought to identify central effector mechanisms of  IL-8–activated and –recruited neutrophils. 
We and others have shown a key role of  NETosis in COVID-19–associated immunothrombosis (35–37). 
Figure 3. A systemic and autocrine neutrophil IL-8 loop in COVID-19. (A and B) UMAP of cells from scRNA-Seq bronchioalveolar lavage data in Wauters et 
al. (26). Annotated cell type in UMAP and feature plot of IL-8 expression by patient population. (C) Violin plot of neutrophil IL-8 expression by patient pop-
ulation in Wauters et al. (26) (n [neutrophils] = 431 for mild and n = 6117 for severe COVID-19, n = 788 for mild non–COVID-19 pneumonia and n = 1 for severe 
non–COVID-19 pneumonia). Since only 1 severe non–COVID-19 pneumonia neutrophil was detected in BALF derived from healthy patients, no violin plot 
depicting IL-8 production in this patient population is shown. Unpaired Student’s t tests. (D) Violin plot of IL-8 expression by cell type and patient population 
of Wauters et al. (26), including neutrophils. (E) IL-8 production assay schematic. (F) IL-8 production assay results. One-way ANOVA with post hoc Dunnett’s 
multiple comparisons test comparing IL-8 to the other conditions. n = 4 neutrophil donors. Mean ± SEM is shown. *P < 0.05, **P < 0.01, ***P < 0.001.
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To investigate whether IL-8 might contribute to NET formation in COVID-19, we exposed neutrophils iso-
lated from healthy donors to IL-8: IL-8 induced a marked increase in NET formation, but also led to a 
pronounced granule release (Figure 4, A and B). Considering the strong degranulation phenotype observed 
in vitro, we profiled granule contents in our COVID-19 proteome data set. Indeed, most granule proteins in 
primary/azurophilic (such as myeloperoxidase, MPO, and lysozyme), secondary/specific (such as CAMP), 
as well as tertiary/gelatinase (such as cathepsin S) and secretory vesicles (such as TREM1) were depleted 
from neutrophils in patients with SARS-CoV-2 pneumonia, suggesting degranulation (Figure 4C and Supple-
mental Figure 3, A–C) (38). In line with this result, granule scores of  the major granule entities as well as a 
computed total granule score were decreased when comparing severe COVID-19 to healthy control patients 
(Figure 4, D and E). Azurophilic granules, known to contain neutrophil proteases such as Cathepsin G and 
Neutrophil elastase (ELANE), play a critical role in intravascular immunothrombosis (39, 40). Therefore, we 
examined the correlation of  azurophilic granule score and D-dimer levels as surrogate parameter of  systemic 
coagulation. Azurophilic granule score correlated negatively with D-dimer levels (Figure 4F), linking neutro-
phil degranulation with coagulation activation. Interestingly, RNA-sequencing data has identified increased 
mRNA content of  granule proteins such as MPO and ELANE in immature neutrophils emerging in severe 
COVID-19, further supporting the notion that not a change in expression but pronounced degranulation is 
responsible for the observed depletion of  granule proteins (21).
To identify additional neutrophil-mediated prothrombotic mechanisms, we next examined neutrophil 
associated coagulation and complement factors. Intermediate and severe COVID-19 neutrophils were char-
acterized by an increased detection of  multiple procoagulant proteins (Supplemental Figure 3D). Analysis 
of  all detectable coagulation cascade proteins revealed that particularly fibrinogen (FGA, FGG, FGB), as 
well as coagulation factors FV, FX, and FIX were increased (Figure 4G). Both fibrinogen and the platelet 
marker P selectin, possibly reflecting platelet-neutrophil aggregate formation (12), correlated with the sys-
temic prothrombotic state as assessed by D-dimer levels, whereas ELANE showed a strong inverse correla-
tion, underlining the degranulated phenotype (Figure 4, H and I).
The complement system has been shown to contribute to both neutrophil activation, NET formation 
and disease progression in COVID-19, with severe cases exhibiting increases in plasma levels of  both classi-
cal and alternative complement components (14, 41, 42). Neutrophils from patients with severe COVID-19 
were characterized by increased detection of  classical complement pathway components, such as C1R and 
C1S (Supplemental Figure 3, E and F). In addition, complement factors of  the terminal complement com-
plex (TCC), C5, C6, C7, C8 and C9, were significantly increased in neutrophils from intermediate and 
patients with severe COVID-19 (Supplemental Figure 3G). TCC formation is associated with increased 
platelet activation and hypercoagulability (14, 42, 43). Indeed, protein abundance of  TCC and C1 on neu-
trophils correlated with fibrinogen on neutrophils, further indicating a role of  neutrophils in driving a proco-
agulant phenotype in severe COVID-19 (Supplemental Figure 3, I and J). We also detected lower levels of  
the complement 5 receptor 1 (C5AR1/CD88) in patients with COVID-19 (Supplemental Figure 3H). Inter-
estingly, the anaphylatoxin complement 5a (C5A) can directly bind the N-protein of  SARS-CoV-2, and C5A 
levels have been shown to be elevated in critical COVID-19 (41). Given that C5A binding to neutrophils can 
trigger hyperactivation (44), the reduction of  C5AR1 observed in our dataset may be due to C5A-induced 
degranulation and subsequent cleavage of  C5AR1 from the neutrophil surface (45).
In summary, our data highlight multiple prothrombotic pathways in severe COVID-19 neutrophils — 
namely (a) NETosis, (b) direct engagement of  the coagulation and (c) complement cascade, and (d) enhanced 
granule release. In addition, our in vitro findings link both neutrophil degranulation and NET formation to 
IL-8 exposure. This suggests that the high levels of  IL-8 detected in plasma of  patients with severe COVID-19 
(7, 8, 46) may play a pivotal role in driving a prothrombotic neutrophil phenotype.
Therapeutic blockade of  IL-8 reduces COVID-19–associated neutrophil activation in vitro and attenuates ARDS- 
related microthrombosis in vivo. Based on the above findings, we hypothesized that IL-8–induced signaling may 
be one of  the culprit pathways for SARS-CoV-2–induced neutrophil activation and recruitment loops that 
drive neutrophil-induced lung injury. Therefore, we assessed the possibility to therapeutically interfere with 
autocrine IL-8 production in neutrophils. To this end, we isolated neutrophils from healthy donors, stimulated 
them and assessed IL-8 production in response to either IL-8 or the NET-inducing agent PMA (methods see 
Figure 3E). The effect of  both IL-8 and PMA on autocrine IL-8 secretion was reduced when incubating neu-
trophils with either an anti–IL-8 antibody or reparixin, a clinically available, oral IL-8 receptor (CXCR-1/-2) 
blocker (47, 48), suggestive of  autocrine, self-sustaining IL-8 production loops in neutrophils (Figure 5A).
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Figure 4. COVID-19 neutrophils are characterized by IL-8–induced degranulation and drive a systemic prothrombotic phenotype. (A) NETing and degranulated 
neutrophils as percentage of all neutrophils with control treatment of IL-8. Paired 2-sided Student’s t test. (B) Representative images of control and IL-8 treated 
neutrophils. Stars show degranulation, arrows NETs. Scale bar: 10 μm. ALPL, alkaline phosphatase; MPO, myeloperoxidase. (C) Heatmap of mean azurophilic 
granule protein abundance by group. (D) Box plot of overall granule score calculated from log-scaled abundance values (see methods) by group. One-way ANOVA 
with post hoc Tukey’s multiple comparisons test between all groups. (E) Box plots of all 4 granule scores calculated from log-scaled abundance values (see 
Methods) by group. Two-sided unpaired Student’s t test between controls and intermediate or severe COVID-19. (F) Linear regression of clinically measured D- 
dimer [μg/mL] and azurophilic granule score of neutrophil proteins of patients with COVID-19. (G) Heat map mean of coagulation cascade protein abundance by 
group. (H) Correlation matrix of clinically measured D-dimer and Horowitz index and neutrophil protein abundance of patients with COVID-19. Pearson r is shown 
in each box and as a heatmap, P values is in brackets. (I) Linear regression of D-dimer [μg/mL] and neutrophil fibrinogen protein abundance of patients with 
COVID-19. (F and I) P value signifies slope significantly non-zero. 95% confidence interval shown in gray. n = 5 severe and 9 intermediate patients with COVID-19. 
(C–E and G) n = 9 healthy control, n = 5 pneumonic controls, n = 5 severe COVID-19, and n = 9 intermediate COVID-19. *P < 0.05, **P < 0.01, ***P < 0.001.
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Next, we exposed neutrophils derived from healthy donors to plasma isolated from either healthy 
donors or patients with COVID-19 pneumonia (Figure 5B). COVID-19 plasma induced neutrophil activa-
tion even after a short incubation period, that could be partially attenuated by IL-8 blockade (Supplemental 
Figure 4, A and B). Correspondingly, neutrophil degranulation and NET formation induced by COVID-19 
plasma were reduced upon blockade of  IL-8 signaling using either an anti–IL-8 antibody or reparixin (Fig-
ure 5, C and D). In fact, blocking IL-8 in COVID-19 plasma with a neutralizing, monoclonal anti–IL-8 
antibody reduced COVID-19 induced NETosis in neutrophils by over 80% (Figure 5C).
Finally, to confirm our results in vivo, we employed a mouse model of  COVID-19-associated respiratory 
failure (49). In transgenic mice expressing the human ACE2 (hACE2) receptor, intranasal exposure to LPS 
and recombinant SARS-CoV-2 spike protein led to pulmonary microthrombosis, mimicking immunothrom-
bosis observed in human lungs (Figure 6A and Supplemental Figure 4D) (12, 50). When comparing hACE2 
negative mice with hACE2 expressing littermates, clinical severity and pulmonary microthrombosis were 
enhanced in hACE2-expressing mice treated with both LPS and SARS-CoV-2 spike protein (Supplemental 
Figure 4, E and F) (50). This effect is dependent on hACE2 expression and spike protein binding, as hACE2 
expressing littermates challenged with LPS, without spike protein, did not show enhanced microthrombosis 
or increased clinical severity (Supplemental Figure 4, E and F), confirming spike protein–mediated pulmo-
nary endotheliopathy (51). In patients with COVID-19, neutrophils binding of  fibrinogen correlated pos-
itively with parameters of  coagulation activation assessed by D-dimer (Figure 4I). Indeed, the number of  
fibrinogen-binding intravascular neutrophils was also increased in this mouse model, specifically for spike 
protein–treated hACE2-positive animals (Supplemental Figure 4G). Although IL-8 itself  is not expressed in 
mice, its homologues CXCL-1, CXCL-2, and GCP-2/CXCL-6 signal via the same receptor pair (CXCR-1/ 
-2) and exert similar functions (52, 53). Blocking IL-8–like signaling with reparixin resulted in a trend toward 
clinical improvement of  hACE2 mice at 24 h, as compared with control animals (Figure 6B and Supplemen-
tal Figure 4I). Reparixin also reduced fibrinogen binding by intravascular neutrophils (Figure 6C). Finally, we 
observed that spike protein–induced pulmonary microthrombosis was significantly attenuated by reparixin 
treatment in this mouse model of  COVID-19 immunopathology (Figure 6D and Supplemental Figure 4H).
Figure 5. Therapeutic blockade of 
IL-8 reduces COVID-19–associated 
neutrophil activation in vitro. (A) 
IL-8 production and blocking assay 
similar to Figure 2E. One-way 
ANOVA with post hoc Dunnett’s 
multiple comparisons test compar-
ing IL-8 to the other conditions. n 
= 5 healthy neutrophil donors. (B) 
Illustration of in vitro experiment: 
Neutrophils from healthy donors 
were exposed to plasma from 
patients with severe COVID-19 and 
pretreated with vehicle, anti–IL-8 
antibody or the CXCR-1/-2 antag-
onist reparixin. Degranulation, 
NETosis and surface expression of 
activation markers were assessed 
by microscopy and flow cytome-
try, respectively. (C) NETing and 
degranulated neutrophils as per-
cent of healthy neutrophils stim-
ulated with COVID-19 plasma and 
nothing, anti–IL-8 antibodies or 
reparixin. Paired 2-sided Student’s 
t test, n = 7 plasma samples from 
patients with COVID-19. (D) Rep-
resentative images of COVID-19 
plasma and COVID-19 plasma and 
anti–IL-8 incubated neutrophils. 
Stars show degranulation, arrows 
NETing. Scale bar: 10 μm. *P < 
0.05, **P < 0.01, ***P < 0.001.
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Discussion
Immunopathology caused by dysregulated cellular responses in life-threatening COVID-19 has been shown 
to contribute to local and remote organ damage (9). Moreover, dysregulation of the myeloid compartment, 
characterized by the emergence of immature neutrophil populations in peripheral blood, along with a global 
skewing toward a procoagulant neutrophil state lead to thrombo-occlusive events (7–9, 21, 32, 33, 54, 55). 
Uncontrolled release of cytokines by innate immune cells might drive these self-destructive, immunopathologi-
cal loops, but mechanistic studies to highlight possible therapeutic targets remain scarce (7, 32, 33, 56).
Using mass-spectrometric analyses, we provide a deep proteome of COVID-19 neutrophils. Detecting more 
than 5000 proteins, our data allow for a broad understanding of neutrophil biology in this disease; in con-
trast to RNA sequencing, this neutrophil proteome also enables analysis of protein binding and release and 
reflects the actual functional state of the cells in vivo. This is specifically of interest considering previous reports 
showing that in neutrophils, transcript abundance may not necessarily correlate with respective protein levels 
(57). This observation is also highlighted in our data set, in which we observe depletion of granule proteins 
in severe COVID-19, whereas prior work using RNA sequencing has described increased granule protein- 
encoding transcripts (21). These diverging results can be reconciled by granule release, which cannot be captured 
by sequencing technology. We identify additional severe proteomic perturbations in neutrophils from patients 
with COVID-19: Increased ISG products in neutrophils from patients with COVID-19 with mild-to-moderate 
severity indicate an antiviral neutrophil response to SARS-CoV-2. In severe COVID-19, this initially protective 
response may deteriorate into a hyperactivated and procoagulant phenotype distinct from other viral pneumo-
nias: When comparing moderate disease and respiratory failure, we uncovered a dominant proteomic signature 
indicative of IL-8 production and signaling. Through analysis of bronchoalveolar lavage scRNA-Seq data and in 
vitro experiments, we confirmed IL-8 production by both pulmonary and circulating neutrophils, which might 
explain their mobilization and influx into the failing lung. Of note, IL-8 mRNA transcription was accentuated in 
alveolar neutrophils from severely ill patients, and in vitro incubation of neutrophils with IL-8 in turn triggered 
prominent IL-8 release. Other cytokines like IL-1β and IL-6, which have been linked to COVID-19 severity and 
the ensuing cytokine storm (27, 30–32), did not exhibit comparable increases in pulmonary neutrophils and did 
Figure 6. Therapeutic blockade of IL-8 signaling attenuates ARDS-related microthrombosis in vivo. (A) Illustration of in vivo SARS-CoV-2 S1 spike 
protein–induced lung injury mouse model. (B) Clinical sepsis score at 24 hours after S1 spike protein–induced lung injury for control and reparixin-treated 
hACE2 mice. (C) Quantification and representative micrographs of fibrinogen-positive/fibrinogen-binding neutrophils in one vessel in the lungs of control 
or reparixin-treated mice. Scale bar: 10 μm. (D) Quantification and representative micrographs of microthrombi in lungs of vehicle or reparixin-treated 
mice. Vessel borders are shown with dashed white lines. Scale bar: 50 μm. (B–D) Two-tailed unpaired Student’s t test, n = 4 per group. Data are shown  
as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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not elicit IL-8 release from blood neutrophils in vitro. These data indicate systemic and autocrine IL-8 loops 
to be central to neutrophil-driven immunopathology. Of note, this pathway does not explain the phenotype 
of intermediate severity neutrophils, suggesting the involvement of additional signaling cascades. Focusing on 
critical disease, recent studies have identified a strong link between circulating IL-8 plasma levels and respiratory 
failure as well as SARS-CoV-2–associated mortality (8, 32). We confirm these findings by showing that plasma 
IL-8 levels are selectively elevated in severe, but not in mild-to-moderate COVID-19 or non–COVID-19 patients.
We further investigated how neutrophils might mediate their prothrombotic and immunopathological 
potential in COVID-19. We identified multiple so far unrecognized prothrombotic pathways linking neutro-
phil activation to hypercoagulability: In addition to NET formation and platelet-neutrophil interplay, we high-
light increased detection of  coagulation and complement factors, as well as neutrophil granule release as key 
aspects of  severe COVID-19. These data are in line with previous observations of  both increasing formation 
of  aggregates consisting of  neutrophils and activated platelets as well as binding/production of  complement 
factors by neutrophils and complement-driven immunothrombosis in COVID-19 (12, 14, 58).
We therefore hypothesized that targeting IL-8 may interfere with this vicious cycle of  neutrophil activa-
tion and prothrombotic phenotype (37). Here, we show that anti–IL-8 antibodies and targeted inhibition of  
IL-8 signaling by the CXCR-1/-2 blocker reparixin reduced neutrophil activation, degranulation and NET 
formation caused by COVID-19 plasma. To validate our findings in vivo, we established a novel model of  
SARS-CoV-2 spike protein and LPS-induced acute lung injury that mimics previous findings from human 
disease, in particular an increase in pulmonary microthrombi and procoagulant neutrophils. Given that this 
model does not require extensive safety requirements compared with live SARS-CoV-2 or other proxy viruses, 
our spike protein–dependent model may serve as versatile experimental basis for further COVID-19-related 
research. Notably, blocking IL-8–like signaling through CXCR-1/-2 decreased disease severity in our murine 
model of  SARS-CoV-2–associated acute respiratory distress syndrome (ARDS). Confirming our insights 
from the human neutrophil proteome, we observed decreased fibrinogen binding by neutrophils in reparix-
in-treated animals and an attenuation of  pulmonary microthrombosis. These findings are particularly note-
worthy in light of  recent phase 2/3 clinical trials that investigate the use of  reparixin in moderate and severe 
COVID-19 pneumonia (e.g., NCT04794803, now NCT04878055). In addition, we provide evidence for spike 
protein–induced increases in both clinical severity, neutrophil activation and microthrombosis. The mech-
anisms by which addition of  spike protein alone exacerbates acute lung injury in absence of  live virus and 
replication-associated cytolysis remain to be investigated. Notably, binding of  coronavirus spike protein to its 
receptor hACE2 (59) has been shown to result in downregulation of  hACE2 surface expression and hACE2 
shedding for both SARS-CoV-1 (60) and SARS-CoV-2 (51). Given that hACE2 is known to attenuate acute 
lung injury in mouse models of  SARS-CoV-1 mediated ARDS (49, 61), reduced local hACE2 availability and 
subsequent hyperactivation of  angiotensin II–mediated (ATII-mediated) signaling may represent a possible 
mechanism of spike protein–induced endothelial dysfunction and aggravation of  pulmonary damage (51).
In summary, we provide insights into the molecular mechanisms of  IL-8–mediated immunopathology 
in COVID-19 that lay out a promising basis for therapeutic targeting, specifically in patients progressing to 
severe COVID-19.
Methods
Cohort. A total of 40 patients were included in our study (n = 22 patients with RT-PCR–confirmed COVID-19 
and n = 18 control patients without COVID-19). For proteomics analysis we recruited a total of 28 patients. Of  
these, 14 were hospitalized, 5 of whom required invasive ventilation (CoV_sev); all CoV_sev patients met the 
Berlin Criteria for ARDS (62). In addition, 5 patients with viral pneumonias and 9 healthy controls were includ-
ed. Details of our cohort are described in Nicolai et al. (12). For in vitro validation experiments, 7 patients with 
COVID-19 (4 male patients, mean age 65) and 5 healthy volunteers were recruited. Patients with COVID-19 
were divided into a group of severe cases requiring intubation and intensive care treatment (CoV_sev, n = 11), 
and a group of intermediate severity (CoV_int, n = 11), which were hospitalized. Control patients were divided 
into non-pulmonary controls (Ctrl, n = 13), and patients with other viral pneumonias (Ctrl_pneu, n = 5). Horow-
itz indices (paO2/FiO2) of CoV_sev patients were derived from ventilation parameters or approximated (12).
For assessment of plasma IL-8 levels, samples from a total of 133 patients, who were admitted to LMU 
University Hospital in Munich for suspected or confirmed COVID-19 were included (Patient characteristics in 
Supplemental Table 4). Plasma samples were measured using a Proximity Extension Assay (PEA, Olink Pro-
teomics) as described previously (63).
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Neutrophil preparation from whole blood. Patient blood was mixed with a Lysing-PFA-Fixation solution 
containing Heparin, distilled water, and FACS Lysing Solution (BD). Lysates were centrifuged and frozen. 
Samples were thawed, spun down, and stained. After adding staining, neutrophils were sorted (Gating: 
Singlets>Size>CD45+>SSC vs CD15>Neutrophils). More than 80,000 neutrophils were sorted per sample. 
After sorting, neutrophils were resuspended in 2% SDS in 50 mM TRIS Buffer (pH 8) and boiled at 95°C 
and 100 rpm for 30 minutes.
Sample preparation for mass spectrometry and analysis. For proteomics analysis, samples were boiled in SDS 
buffer and subjected to SP3-based cleanup and tryptic digest (64). To enable multiplexing, samples were 
labeled with TMTpro 16-plex reagents (Thermo Fisher Scientific) (65). A total of  5 μg peptide/sample was 
assigned to channels 1–12. Pooled plexes were subjected to high-pH HPLC separation into 24 fractions. An 
estimate of  1 μg each fraction was measured on a Q Exactive HF-X mass spectrometer (Thermo Fisher 
Scientific). For database search, MaxQuant version 1.6.10.43 (66) was used while enabling TMTpro 16-plex 
reporter ion quantitation with a PIF setting of  0.5. Downstream analysis was done with R. For quantitation, a 
minimum of 75% valid TMT reporter ion intensities was required. The remaining missing values were imput-
ed by employing k-nearest neighbor algorithm. Corrected reporter ion intensities were normalized against the 
internal reference sample and scaled using median-median absolute deviation (median-MAD) normalization. 
For significance calling 2-sample moderated, 2-tailed Student’s t testing as well as moderated F testing was 
applied (limma R package) (67). P values were adjusted using the Benjamini-Hochberg method.
Neutrophil activation with patient plasma. Neutrophils were isolated using the EasySep Neutrophil Isolation 
Kit (Stemcell Technologies), counted, and resuspended in RPMI containing L-glutamine and 5% FCS. Neu-
trophils were exposed to plasma (10% final concentration) derived from healthy donors (n = 4) or patients 
with COVID-19 (n = 7) and subsequently stained for indicated activation markers. For selected subgroups, 
human IL-8 (MilliporeSigma, I1654), anti-human IL-8 antibody (MilliporeSigma, I2519), or reparixin (20 
μM, SelleckChem, S8640) were added to either plasma or neutrophils 20 minutes before neutrophil exposure 
to plasma. Cells were incubated at 37°C and 5% CO2 for 1 hour, fixated using 1% PFA. Mean fluorescent 
intensities (MFIs) of  neutrophils (singlets>size>CD15++CD16+) were assessed.
In a separate series of experiments, isolated healthy neutrophils were added to poly-L lysine coated Ibidi 
μ-slides and treated with plasma (20% final concentration) and/or inhibitors as described above. Neutrophil 
granules, released vesicles and NETS were stained using antibodies against myeloperoxidase (MPO, R&D Sys-
tems, AF3667) and neutrophil alkaline phosphatase (ALPL, MilliporeSigma, HPA008765) and secondary anti-
bodies (anti-goat AF594, anti-rabbit AF647, 1:200, Invitrogen) along with 4′,6-diamidin-2-phenylindole (1:1000) 
and SytoxGreen (Thermo Fisher Scientific, S7020, 500 nM final concentration, see Supplemental Figure 4C).
Assessment of  neutrophil IL-8 secretion in vitro. Isolated neutrophils (n = 5) were exposed to human IL-8 (20 ng/
mL, MilliporeSigma I1654), human IL-1β (20 ng/mL), human IL-6 (20 ng/mL, BioLegend 570804) or phor-
bol myristate acetate (PMA, 100 nM, EnzoLifeSciences, BML-PE160-0001) for 1 hour at 37°C. Subsequently, 
neutrophils were washed twice, spun down, resuspended in RPMI, and incubated for 2 hours. RPMI contained 
either an IL-8 blocking antibody (10 μg/mL), reparixin (20 μM), or both. In some experiments, neutrophils were 
fixated with 4% PFA to ensure that measured IL-8 levels in nonfixated samples reflected secretion and were not 
simply a carryover of recombinant IL-8. Stimulated neutrophils were spun down, and supernatant was collect-
ed and snap-frozen on dry ice. IL-8 content of neutrophil supernatants was assessed using an IL-8 ELISA kit 
(Abcam, ab46032) and a plate reader (450 nm, Tecan Infinite F200).
In vivo model of  SARS-CoV-2 S-protein and LPS-induced ARDS. Mice transgenic for the human ACE2 recep-
tor (K18-hACE2, B6.Cg-Tg(K18-ACE2)2Prlmn/J, 034860, The Jackson Laboratory) were exposed to 20 μg 
LPS (MilliporeSigma) or LPS 20 μg and 10 μg SARS-CoV-2 S1 spike protein (Abcam) i.n. to establish the 
model of  spike protein–induced pulmonary injury. hACE2-negative litter mates served as controls. In a sep-
arate series of  experiments, hACE2-positive mice were treated with both LPS and spike protein applied i.n., 
with one group of  animals receiving reparixin (15 μg/g BW i.p.) 1 hour before and 2 hours after LPS/spike 
protein challenge (50, 68). Clinical scoring was performed by a scientist blinded to treatment. Mice were sac-
rificed after 24 hours, and lungs were removed and either processed for histopathological analysis (see below).
Histopathological analysis of  murine lungs. Lung slices were fixated and stained using primary antibodies 
targeting Ly6G (BioLegend, 127632), MPO (R&D Systems, AF3667), CD42b (Abcam, 183345), and Fibrin-
ogen (R&D Systems, AF4786) (12). Stained lung slices were imaged on an inverted Zeiss LSM 880 confocal 
microscope in AiryScan Super Resolution (SR) Mode (magnification, ×20/0.8 obj.), with 5–6 random imag-
es acquired per lung.
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Analysis of  scRNA-Seq data from bronchoalveolar lavage fluid. Count matrices for the scRNA-Seq dataset pub-
lished by Liao and colleagues (25) as well as Wauters et al. (26) were downloaded from GEO (accession 
GSE145926) and the EGA European Genome-Phenome Archive database (EGAS00001004717), respective-
ly. scRNA-Seq data were analyzed using Seurat 3.1.1 (https://github.com/mjoppich/CovidImmune/com-
mit/977e60da8a6b4c03f628193f6348a27a65ba4578; branch, https://github.com/mjoppich/CovidImmune/
tree/jci). A table with annotated cell types and their absolute prevalence is shown in Supplemental Tables 2 
and 3. For cell type–specific analysis, neutrophils were defined according to expression of  population-defining 
gene sets in the Liao et al. data set (e.g., CD16/FCGRIII, S100A9), whereas neutrophils in the scRNA-Seq 
data from Wauters et al. were identified as described by the authors (26).
Data sharing statement. Processed proteomic data are available for quick visual insights online on shiny 
MDC (https://neuprocov.mdc-berlin.de/). This includes graphical interfaces and a protein expression table 
download to compare neutrophil protein dynamics in healthy patients, viral pneumonia, and SARS-CoV-2 
pneumonias. For all other original data, please contact the corresponding authors.
Statistics. Data were analyzed using Excel v16 (Microsoft), Prism v8.3.0. (GraphPad) and R v4.0.3. For 
direct comparisons between 2 groups, unpaired or paired 2-tailed Student’s t tests were used, as indicated. 
For comparisons between groups 1-way ANOVAs with Dunnett’s post hoc tests were used. Only post hoc 
test results are displayed in the graphs. P values of less than or equal to 0.05 are considered significant. For 
proteomic data, the adjusted P value was used to determine significance in case of singular protein abundance 
comparisons. For pathway analysis Cytoscape 3.8.1 with ClueGo 2.5.7 were used (69, 70). The top 100 dif-
ferentially expressed proteins were used, with GO-BP pathways with a P value of less than 0.05 and medium 
network specificity shown. The network is displayed by significance of the groups’ individual pathways, with 
arrows signifying direction of association between pathways. The network term shown is the one that is the 
most significant of its group. Individual patient data are represented as dots, unless otherwise indicated. Pro-
tein scores were computed as the mean of the median-MAD column based on normalized protein abundance 
(compare Supplemental Table 1). Scores were determined after an extensive literature search: For granule 
scores, Adrover et al. (38) was used as a reference, for procoagulant and complement groups, all detectable 
coagulation cascade factors and complement factors were included (71–75). For IL-8–related proteins, a liter-
ature search for detectable relevant pathway proteins was used for the score (76–88). For regression analyses 
Prism or R with corrplot (89) were used. Gray lines represent best-fit line, and the gray area the 95% confidence 
interval. Pearson r and P values (test for slope non-zero) are shown in plots.
Study approval. In accordance with the Declaration of  Helsinki, informed consent of  the patients or 
guardians was obtained. Patients with COVID-19 and included control patients are part of  the COVID-19 
Registry of  the LMU University Hospital Munich (CORKUM, WHO trial ID DRKS00021225). Pseud-
onymized data were used for analysis, and the study was approved by the ethics committee of  LMU Munich 
(no. 20-245 and 19-274).
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